Real-World Insights into Avatrombopag's Effectiveness and
Safety in Adults with Primary Immune Thrombocytopenia: A
Retrospective Analysis from Central and Eastern Europe

J 2026

Real-World Insights into Avatrombopag's Effectiveness and Safety in Adults with Primary Immune Thrombocytopenia: A Retrospective Analysis from Central and Eastern Europe

SKOPEC, Barbara; Drazen PULANIC a Libor ČERVINEK

Základní údaje

Originální název

Real-World Insights into Avatrombopag's Effectiveness and Safety in Adults with Primary Immune Thrombocytopenia: A Retrospective Analysis from Central and Eastern Europe

Autoři

SKOPEC, Barbara; Drazen PULANIC a Libor ČERVINEK

Vydání

Acta Haematologica, BASEL, KARGER, 2026, 0001-5792

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.100 v roce 2024

Označené pro přenos do RIV

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1159/000547576

UT WoS

001573409300001

Klíčová slova anglicky

Avatrombopag; Thrombopoietin receptor agonists; Purpura; Retrospective studies; Thrombocytopenia

Štítky

14110212

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 3. 2026 11:33, Mgr. Tereza Miškechová

Anotace

V originále

Introduction: Primary immune thrombocytopenia (ITP) is an autoimmune condition marked by low platelet counts, leading to symptoms such as bleeding. Avatrombopag (AVA), a second-generation thrombopoietin receptor agonist, has shown efficacy in clinical trials but lacks extensive real-world data, particularly in Central and Eastern Europe (CEE). This study aims to evaluate the effectiveness and safety of AVA in routine clinical practice for ITP patients across CEE countries. Methods: A multicenter, noninterventional, retrospective analysis was conducted in Slovenia, Croatia, and the Czech Republic, involving 41 patients treated with AVA for primary ITP. The primary endpoint was achieving a platelet response at week 8 (W8). Results: AVA treatment resulted in a 68.3% platelet response rate by W8, with a significant increase in median platelet counts. Rescue medication use decreased post-AVA initiation, and many patients reduced or discontinued steroids. AVA was well-tolerated, with only one adverse event reported and no significant bleeding events. Conclusion: AVA is effective in improving platelet counts and reducing medication dependency in ITP patients in CEE countries. It offers a viable treatment option with a favorable safety profile, supporting its use across different ITP stages and patient demographics.

Citovat

SKOPEC, Barbara; Drazen PULANIC a Libor ČERVINEK. Real-World Insights into Avatrombopag's Effectiveness and Safety in Adults with Primary Immune Thrombocytopenia: A Retrospective Analysis from Central and Eastern Europe. Acta Haematologica. BASEL: KARGER, 2026, 11 s. ISSN 0001-5792. Dostupné z: https://doi.org/10.1159/000547576.

@article{2557773,
   author = {Skopec, Barbara and Pulanic, Drazen and Červinek, Libor},
   article_location = {BASEL},
   doi = {https://doi.org/10.1159/000547576},
   keywords = {Avatrombopag; Thrombopoietin receptor agonists; Purpura; Retrospective studies; Thrombocytopenia},
   language = {eng},
   issn = {0001-5792},
   journal = {Acta Haematologica},
   title = {Real-World Insights into Avatrombopag's Effectiveness and Safety in Adults with Primary Immune Thrombocytopenia: A Retrospective Analysis from Central and Eastern Europe},
   url = {https://karger.com/aha/article/doi/10.1159/000547576/932292/Real-World-Insights-into-Avatrombopag-s},
   year = {2026}
}

TY  - JOUR
ID  - 2557773
AU  - Skopec, Barbara - Pulanic, Drazen - Červinek, Libor
PY  - 2026
TI  - Real-World Insights into Avatrombopag's Effectiveness and Safety in Adults with Primary Immune Thrombocytopenia: A Retrospective Analysis from Central and Eastern Europe
JF  - Acta Haematologica
PB  - KARGER
SN  - 00015792
KW  - Avatrombopag
KW  - Thrombopoietin receptor agonists
KW  - Purpura
KW  - Retrospective studies
KW  - Thrombocytopenia
UR  - https://karger.com/aha/article/doi/10.1159/000547576/932292/Real-World-Insights-into-Avatrombopag-s
N2  - Introduction: Primary immune thrombocytopenia (ITP) is an autoimmune condition marked by low platelet counts, leading to symptoms such as bleeding. Avatrombopag (AVA), a second-generation thrombopoietin receptor agonist, has shown efficacy in clinical trials but lacks extensive real-world data, particularly in Central and Eastern Europe (CEE). This study aims to evaluate the effectiveness and safety of AVA in routine clinical practice for ITP patients across CEE countries. Methods: A multicenter, noninterventional, retrospective analysis was conducted in Slovenia, Croatia, and the Czech Republic, involving 41 patients treated with AVA for primary ITP. The primary endpoint was achieving a platelet response at week 8 (W8). Results: AVA treatment resulted in a 68.3% platelet response rate by W8, with a significant increase in median platelet counts. Rescue medication use decreased post-AVA initiation, and many patients reduced or discontinued steroids. AVA was well-tolerated, with only one adverse event reported and no significant bleeding events. Conclusion: AVA is effective in improving platelet counts and reducing medication dependency in ITP patients in CEE countries. It offers a viable treatment option with a favorable safety profile, supporting its use across different ITP stages and patient demographics.
ER  -

SKOPEC, Barbara; Drazen PULANIC a Libor ČERVINEK. Real-World Insights into Avatrombopag's Effectiveness and Safety in Adults with Primary Immune Thrombocytopenia: A Retrospective Analysis from Central and Eastern Europe. \textit{Acta Haematologica}. BASEL: KARGER, 2026, 11 s. ISSN~0001-5792. Dostupné z: https://doi.org/10.1159/000547576.

Přehled o publikaci